ATRA

Company Overview — What Does Atara Biotherapeutics, Inc. Do?

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherapeutics, Inc. (ATRA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Pascal Touchon and employs approximately 330 people, headquartered in Brisbane, California. With a market capitalization of $42M, ATRA is one of the notable companies in the Healthcare sector.

Atara Biotherapeutics, Inc. (ATRA) Stock Rating — Reduce (April 2026)

As of April 2026, Atara Biotherapeutics, Inc. receives a Reduce rating with a composite score of 30.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ATRA ranks #3,825 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Atara Biotherapeutics, Inc. ranks #644 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATRA Stock Price and 52-Week Range

Atara Biotherapeutics, Inc. (ATRA) currently trades at $4.65. The stock lost $0.18 (3.7%) in the most recent trading session. The 52-week high for ATRA is $19.14, which means the stock is currently trading -75.7% from its annual peak. The 52-week low is $3.92, putting the stock 18.6% above its annual trough. Recent trading volume was 87K shares, suggesting relatively thin trading activity.

Is ATRA Overvalued or Undervalued? — Valuation Analysis

Atara Biotherapeutics, Inc. (ATRA) carries a value factor score of 81/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 2.72x, compared to the Healthcare sector average of 23.63x — a discount of 88%. The price-to-sales ratio is 0.24x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ATRA trades at 1.93x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, Atara Biotherapeutics, Inc. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

Atara Biotherapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Atara Biotherapeutics, Inc. (ATRA) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at 70.1% versus the sector average of -33.1%.

On a margin basis, Atara Biotherapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -25.0% (sector: -66.1%). Net profit margin stands at -31.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -87.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATRA Debt, Balance Sheet, and Financial Health

Balance sheet data for ATRA is evaluated through our stability factor. The current ratio is 0.82x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $0. Cash and equivalents stand at $6M.

ATRA has a beta of 1.16, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Atara Biotherapeutics, Inc. is 21/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Atara Biotherapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Atara Biotherapeutics, Inc. reported revenue of $159M and earnings per share (EPS) of $2.61. Net income for the quarter was $14M. Gross margin was 100.0%. Operating income came in at $17M.

In FY 2025, Atara Biotherapeutics, Inc. reported revenue of $121M and earnings per share (EPS) of $2.61. Net income for the quarter was $33M. Revenue grew -6.3% year-over-year compared to FY 2024. Operating income came in at $36M.

In Q3 2025, Atara Biotherapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.32. Net income for the quarter was $-4M. Revenue grew -91.4% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, Atara Biotherapeutics, Inc. reported revenue of $18M and earnings per share (EPS) of $0.20. Net income for the quarter was $2M. Revenue grew -38.6% year-over-year compared to Q2 2024. Operating income came in at $3M.

Over the past 8 quarters, Atara Biotherapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $29M to $159M. Investors analyzing ATRA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATRA Dividend Yield and Income Analysis

Atara Biotherapeutics, Inc. (ATRA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATRA Momentum and Technical Analysis Profile

Atara Biotherapeutics, Inc. (ATRA) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 54/100 reflects moderate short selling activity.

ATRA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Atara Biotherapeutics, Inc. (ATRA) ranks #644 out of 838 stocks based on the Blank Capital composite score. This places ATRA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATRA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATRA vs S&P 500 (SPY) comparison to assess how Atara Biotherapeutics, Inc. stacks up against the broader market across all factor dimensions.

ATRA Next Earnings Date

No upcoming earnings date has been announced for Atara Biotherapeutics, Inc. (ATRA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATRA? — Investment Thesis Summary

The quantitative profile for Atara Biotherapeutics, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 81/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 21/100) increases portfolio risk.

In summary, Atara Biotherapeutics, Inc. (ATRA) earns a Reduce rating with a composite score of 30.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATRA stock.

Related Resources for ATRA Investors

Explore more research and tools: ATRA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATRA head-to-head with peers: ATRA vs AZN, ATRA vs SLGL, ATRA vs VMD.